Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib plus apatinib in platinum-sensitive relapsed ovarian cancer after first-line PARP inhibitor maintenance
ChiCTR2200059352Phase 4Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Apr 2022
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fluzoparib and Rivoceranib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Progression-free survival. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
fluzoparibRivoceranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2200059352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059352.